[1] |
WANG Ruyue, XIE Fei, WANG Xin, LI Hongyu.
Therapeutic effect of lienal polypeptide injection on bone marrow suppression and immunodeficiency in KM mice following chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1000-1007.
|
[2] |
HE Lihua, ZHU Xiuzhi, JIANG Yizhou.
Research progress on immunotherapy for triple-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
|
[3] |
ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin.
Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
|
[4] |
LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui.
Advances in targeted therapy for HER2-positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
|
[5] |
XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua.
Research progress of biomarkers related to the efficacy of HER2 positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
|
[6] |
HOU Qiong, LIU Fei, CHEN Chuanrong.
Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
|
[7] |
QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili.
New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
|
[8] |
CHEN Manxin, ZHANG Bingyu, DAI Min.
Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
|
[9] |
LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao.
Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593.
|
[10] |
WANG Dan, YAN Xiaoli, ZHANG Yuan.
Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
|
[11] |
CHEN Wenjie, WANG Yabing, CHEN Xiaolin, REN Junling, ZHAO Wanjun, CHEN bin.
Advances in the study of iodine-resistant differentiated thyroid cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 116-120.
|
[12] |
LIU Chen, FANG Mengdie, XU Hao, LI Chao, REN Juan, ZUO Bowen, ZHANG Yanmei.
Atractyloside targets the area of action of oncoprotein BORIS to inhibit cancer cell proliferation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1005-1013.
|
[13] |
LI Wei, HU Jiali, WANG Kai, HE Yijing.
Research progress and prospect of immunotherapy in the treatment of melanoma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1053-1064.
|
[14] |
WU Rongrong, CHEN Zhiqiang, JIA Yifei, CHEN Hongqi, WANG Panpan, YAN Ru.
Applications of BGUSs inhibition in tumor prevention and chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 964-974.
|
[15] |
MIN Hang, GUO Mengran, YE Yue, XU Xiaoshuang, ZHEN Donghu.
Research progress of thyroid dysfunctions during treatment with immune-checkpoint inhibitors
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 223-229.
|